N4 Pharma highlights the potential of Nuvec® as a gene therapy delivery platform by successfully completing a pre-clinical, in-vivo oncology study. The results reinforce the findings from an earlier pilot study designed to test the ability to use a monodispersed Nuvec® formulation in an intravenous (“i.v”) route of administration using a DNA plasmid (pDNA) encoding TNF alpha, to assess the tolerance of different doses and to look at tumour regression.
We were pleased to share this news with the life science industry and some key publications in this field have shared the update. You can read more about the progress we’ve made in some of the pieces linked below:
Read the full summary of findings here.
